Abstract: The present invention relates to activated lymphocytes comprising cytokine-induced killer cells in which CD8+CD56+NKG2D+ cells are present at a proportion of 20% or more, and a preparation method therefor, and more particularly, to activated lymphocytes comprising cytokine-induced killing cells which have high tumor cell killing abilities and growth rates and are almost free of side effects because they do not require the combined administration of interleukin-2, and a preparation method therefor.
Type:
Grant
Filed:
May 4, 2020
Date of Patent:
May 6, 2025
Assignee:
GREENCROSSCELL
Inventors:
Gyou Chul Jung, Dong Young Kim, Ji Min Lee
Abstract: The present invention relates to activated lymphocytes comprising cytokine-induced killer cells in which CD8+CD56+NKG2D+ cells are present at a proportion of 20% or more, and a preparation method therefor, and more particularly, to activated lymphocytes comprising cytokine-induced killing cells which have high tumor cell killing abilities and growth rates and are almost free of side effects because they do not require the combined administration of interleukin-2, and a preparation method therefor.
Type:
Application
Filed:
May 4, 2020
Publication date:
May 26, 2022
Applicant:
GREENCROSSCELL
Inventors:
Gyou Chul JUNG, Dong Young KIM, Ji Min LEE
© 2025 Justia
